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Pre-clinical evaluation of second generation PIM
inhibitors for the treatment of T-cell acute 
lymphoblastic leukemia and lymphoma 
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell
lymphoblastic lymphoma (T-LBL) are aggressive hemato-
logic malignancies that are currently still treated by high-
dose chemotherapy possibly followed by hematopoietic
stem cell transplantation.1 Despite important progress in
deciphering the genomic landscape of these diseases, the
transition of novel targeted therapies towards clinical
practice has remained largely unsuccessful.2 T-ALL and T-
LBL, which the World Health Organization regards as
one single disease entity,  can be classified into different
molecular genetic subtypes based on the aberrant expres-
sion of specific transcription factor oncogenes, such as
LYL1, TLX1, TLX3, HOXA, NKX2-1, TAL1 or LMO2.2
Within these genetic subclasses, a variety of co-operative
lesions converge towards activation of specific pathways,
such as JAK-STAT or PI3K-AKT signaling.2 Interestingly,
JAK-STAT pathway mutations seem to be more prevalent
in LYL1+, TLX1+, TLX3+ and HOXA+ tumors, whereas
mature TAL1+ leukemias/lymphomas more often display
PI3K/AKT alterations.2
PIM1 is a highly conserved serine/threonine kinase
involved in cell-cycle progression, transcription, apopto-
sis, drug resistance and cellular metabolism through
phosphorylation of a myriad of known downstream tar-
gets.3 Formal proof of its oncogenic activity emerged
from the analysis of Pim1 transgenic mice, which sponta-
neously developed T-cell lymphomas with a latency of
several months.4 At the transcriptional level, PIM1 is a
canonical JAK-STAT target gene that can be activated
downstream of cytokine signaling. Recently, a number of
studies have all shown that PIM1 might act as an attrac-
tive molecular target in human T-ALL.5-7 Indeed, recent
work identified a case of adult T-ALL in which aberrant
activation of PIM1 was driven by the T-cell receptor
(TCR) translocation t(6;7)(p21;q34) (TCRβ-PIM1).7 In
addition, PIM1 activation was also found to be more
broadly implicated in T-ALL disease biology downstream
of mutational activation of the JAK-STAT signaling path-
way.6,7 Although these studies clearly point towards PIM1
as a novel therapeutic target for the treatment of T-ALL,
initial drug evaluation experiments have largely been
focused on human T-ALL and T-LBL cell lines, which
often fail to provide an accurate representation of the pri-
mary disease.5,6 Therefore, additional in-depth pre-clinical
in vivo evaluation of PIM inhibitors using patient-derived
xenograft models of human T-ALL and T-LBL will be
required to further facilitate the translation of these find-
ings into clinical practice in the near future.
Here, we report the identification of a similar TCRβ-
PIM1 translocation, t(6;7)(p21;q34), as previously
described,7 in a case of pediatric T-LBL, suggesting that
these PIM1 rearrangements are a rare but recurrent
genetic abnormality in both pediatric and adult T-ALL
and T-LBL. For this particular T-LBL case (see the Online
Supplementary Methods for clinical information), initial
FISH analysis revealed the presence of a TCRβ transloca-
tion in the major leukemic clone at diagnosis. Using
Targeted Locus Amplification (TLA),8 with the TCRβ
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Figure 1. In vivo PIM1 inhibition in PIM1high and PIM1low T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LBL)  patients. (A)
Schematic representation of the in vivo treatment schedule used for the PIM inhibitors TP-3654 and AZD1208; 4 mice per group were used. (B) Percentage of
human CD45+ (%hCD45) cells in peripheral blood during treatment (left) and spleen weight of the different treatment groups after completion of treatment
(right). *P<0.05; **P<0.01;  ***P<0.005. (C) Delayed tumor development in TCRβ-PIM1+ T-LBL and TLX3+ PIM1high T-ALL xenografts after short-term in vivo
PIM1 inhibition with TP-3654; 4 mice per group were used. (D) Short-term response of an SIL-TAL1+ PIM1low T-ALL to PIM1 inhibition using TP-3654; 4 mice per
group were used.
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locus as viewpoint, we subsequently identified the
genomic breakpoint of this rearrangement at 133 kb
upstream of the PIM1 proto-oncogene (Online
Supplementary Figure S1A and B). Quantitative RT-PCR
(qPCR) confirmed that this T-LBL patient displayed
strongly enhanced PIM1 expression as compared to nor-
mal CD34+ T-cell precursor cells (Online Supplementary
Figure S1C). Moreover, analysis of a specific SNP
(rs10507) in the 3’UTR of PIM1 confirmed skewed allelic
expression (Online Supplementary Figure S1D).
Furthermore, qPCR analysis revealed that this
t(6;7)(p21;q34)-positive T-LBL was characterized by aber-
rant expression of the TLX1 oncogene (Online
Supplementary Figure S1E), displayed trisomy 8, and con-
tained focal deletions of the known tumor suppressor
genes FHIT, LEF1, IKZF1 and CDKN2A (Online
Supplementary Figure S2).2 Finally, TCRβ-PIM1+ T-LBL
tumor cells also displayed an activating NOTCH1 muta-
tion and a loss-of-function alteration targeting EP300
(Online Supplementary Table S1), but lacked any IL7R-JAK-
STAT pathway mutations.
Using previously published microarray data of primary
T-ALLs (n=64) and sorted subsets of normal human thy-
mocyte precursors,9 we subsequently confirmed that high
expression of PIM1 is largely restricted to LYL1+, TLX1+,
TLX3+ and HOXA+ T-ALLs (Online Supplementary Figure
S3A).6,7 In this cohort, PIM1 expression was also signifi-
cantly correlated with different known JAK-STAT target
genes, such as CISH (Pearson’s r = 0.845, P<10-5) and
STAT4 (Pearson’s r=0.844, P<10-5) (Online Supplementary
Table S2 and Online Supplementary Figure S3B).
Furthermore, treating the TLX3+ IL7Rmut DND-41 cell line
with the JAK inhibitor ruxolitinib led to reduced PIM1
mRNA levels (Online Supplementary Figure S3C) and we
observed higher PIM1 mRNA levels in IL7Rmut/JAKmut
patients versus IL7Rwt/JAKwt in another independent 
T-ALL cohort (n=117) (Online Supplementary Figure S3D),10
further confirming the tight association between PIM1 and
JAK-STAT pathway activation.6,7 This second cohort also
revealed that NKX2-1+ T-ALLs display low levels of PIM1
(Online Supplementary Figure S3E).2 Finally, similar ranges of
PIM1 expression levels were also observed in two inde-
pendent cohorts of primary T-LBL, as analyzed by qPCR
(Online Supplementary Figure S3F and G). Thus, our data
support the notion that PIM1 is activated in a significant
fraction of human T-ALL and T-LBL patient samples, by
rare TCR driven translocations or aberrant activation of
the JAK-STAT signaling pathway.6,7  
Next, in order to firmly validate PIM1 as a bona fide
therapeutic target for the treatment of human T-ALL and
T-LBL, we used two independent second-generation pan-
PIM inhibitors (AZD120811 and TP-365412) to perform
pre-clinical in vivo drug evaluation experiments. For this,
we established a patient-derived xenograft (PDX) model
from pleural effusion tumor material obtained from the
TCRβ-PIM1+ TLX1+ NOTCH1mut T-LBL case. This PDX
represents the primary disease as FISH analysis on PDX
material confirmed the presence of the TCRβ-PIM1
translocation (Online Supplementary Figure S4A).
Moreover, qPCR data showed similar PIM1 expression
levels in primary pleural effusion cells and PDX cells
(Online Supplementary Figure S4B). Treatment of this 
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Figure 2. Transcriptional effects of PIM1 inhibition in xenograft cells of human T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma
(T-LBL). (A) DESeq2 normalized count values for PIM1, SOCS1 and CISH based on RNA sequencing data of DMSO control samples of xenograft spleen cells [col-
lected after 24 hours (h) in culture] obtained from TCRβ-PIM1+ T-LBL, TLX3+ PIM1high T-ALL and SIL-TAL1+ PIM1low T-ALL patients, respectively. (B) Diagonal plots
from RNA sequencing data of xenograft cells obtained from TCRβ-PIM1+ T-LBL, TLX3+ PIM1high T-ALL and SIL-TAL1+ PIM1low T-ALL patients with DMSO normalized
counts on the x-axis versus TP-3654 normalized counts on the y-axis. Up-regulated genes are shown in red, down-regulated genes in blue (pad j < 0.05, |FC|
> 0.5). (C) Gene Set Enrichment Analysis plots for down-regulated genesets upon PIM1 inhibition using TP-3654 in responsive TCRβ-PIM1+ T-LBL and TLX3+
PIM1high T-ALL patient samples. NES: Normalized Enrichment Score. (D) Western blot analysis of MYC (Ser62), total MYC, p70S6K (Thr389) and total 70S6K
upon PIM inhibition by TP-3654 (6 h, 2.5 mM) or AZD1208 (6 h, 2.5 mM) in DND41 T-ALL cells. 
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T-LBL xenograft was initiated when 1% of blasts were
detected in the peripheral blood (PB) and consisted of 3
blocks (5 days on : 2 days off) either of AZD1208 (30
mg/kg, oral gavage), TP-3654 (125 mg/kg, oral gavage),
or the respective controls (Figure 1A). Notably, both PIM
inhibitors caused a significant delay in tumor develop-
ment as evaluated by the percentage of hCD45+ tumor
cells in PB or spleen weight (Figure 1B). Furthermore,
similar patient-derived xenograft models were estab-
lished from a TLX3+ PIM1high PHF6mut NOTCH1mut and a
SIL-TAL1+ PIM1low FBXW7mut NOTCH1mut T-ALL patient
sample (Online Supplementary Figure S4C and D). Notably,
short-term in vivo PIM inhibition experiments (5 consec-
utive days; 125 mg/kg TP-3654, oral gavage) also delayed
tumor development in the TLX3+ PIM1high T-ALL case to a
similar extent as observed for the TCRβ-PIM1+ T-LBL
xenograft (Figure 1C). However, and in contrast, no anti-
leukemic effects were observed in the SIL-TAL1+ PIM1low
patient-derived xenograft (Figure 1D). Given that we did
not see any in vivo effect in the PIM1low case, and other
PIM kinases (PIM2 and PIM3) are practially non-
expressed in these patients (Online Supplementary Figure
S5), we believe that the observed effects are largely due
to specific PIM1 inhibition.
To further investigate the oncogenic role of PIM1 in
primary T-ALL and T-LBL specimens, we subsequently
performed RNA sequencing on biological triplicates of
patient-derived xenograft cells obtained from the TCRβ-
PIM1 PIM1high T-LBL, TLX3+ PIM1high T-ALL and SIL-TAL1+
PIM1low T-ALL cases treated with either DMSO or 1 mM
TP-3654 ex vivo (24 hours) (Online Supplementary Figure
S6). As expected, the transcriptional profiles of the
DMSO control samples confirmed that high PIM1
expression occurred in the absence of JAK-STAT path-
way activation (as evidenced by low expression of the
JAK-STAT target genes SOCS1 and CISH) in the TCRβ-
PIM1+ T-LBL patient sample (Figure 2A), whereas high
PIM1 levels coincided with aberrant activation of JAK-
STAT signaling in the TLX3+ T-ALL case (Figure 2A). In
line with the observed PIM1 levels and the therapeutic
response described above, PIM1 inhibition induced tran-
scriptional changes in the tumor cells from the TCRβ-
PIM1+ PIM1high T-LBL (173 up and 250 down; |FC| >0.5,
padj <0.05) and the TLX3+ PIM1high T-ALL patient sample
(93 up and 218 down; |FC| >0.5, padj<0.05). In contrast, a
limited transcriptional response was observed in the SIL-
TAL1+ PIM1low T-ALL case (25 up, 75 down; |FC|>0.5,
padj<0.05) (Figure 2B). Interestingly, Gene Set Enrichment
Analysis (GSEA) revealed that genes significantly down-
regulated upon PIM1 inhibition in both sensitive T-LBL
and T-ALL samples were enriched for gene sets related to
amino acid deprivation, MYC target genes and tran-
scripts downstream of MTORC1 signaling (Figure 2C,
Online Supplementary Table S3 and Online Supplementary
Figure S7). These effects might, at least in part, be medi-
ated by reduced phosphorylation at previously estab-
lished PIM1 substrates, such as MYC at serine 62 and
p70S6K at threonine 389, upon PIM inhibition, as shown
for DND-41 (PIM1high/TLX3+/IL7Rmut) T-ALL cells (Figure
2D). 
Finally, previous studies, for example in breast cancer,
have shown that PIM1 inhibition can result in loss of
anti-apoptotic MCL1 expression.13 In line with this, PIM1
inhibition by TP-3654 also resulted in decreased MCL1
expression in patient-derived xenograft cells from both
responsive TCRβ-PIM1+ PIM1high T-LBL and TLX3+
PIM1high T-ALL patient samples (Figure 3A).  In contrast,
BCL2 protein levels were not affected by PIM inhibition
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LETTERS TO THE EDITOR
Figure 3. Synergistic effects of PIM1 inhibition and glucocorticoid therapy. (A) Western blot analysis of MCL1 protein levels in ex vivo treated xenograft spleen
cells obtained from TCRβ-PIM1+ T-LBL, TLX3+ PIM1high T-cell acute lymphoblastic leukemia (T-ALL) and SIL-TAL1+ PIM1low T-ALL patients treated with PIM1 inhibitor
TP-3654. (B) Combination treatment of TP-3654 and dexamethasone (72 hours) on an ex vivo co-culture system using tumor material from the TLX1+ TCRβ-
PIM1+ T-cell lymphoblastic lymphoma (T-LBL)  patient. Color code is based on the number of living cells per well. (C) Treatment schedule of in vivo combination
treatment with TP-3654 and dexamethasone; 6 mice per group were used. (D) %hCD45 cells in peripheral blood during treatment for the different treatment
groups. n.s.: not significant. *P<0.05; **P<0.01. (E) Kaplan-Meier curve representing survival during the in vivo combination drug treatment experiment.
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(Online Supplementary Figure S8A). 
Given that sustained MCL1 expression has been asso-
ciated with glucocorticoid resistance in ALL,14 we won-
dered whether PIM1 targeting could also trigger sensiti-
zation towards glucocorticoid treatment in T-LBL and 
T-ALL. Therefore, we used a previously established ex
vivo co-culture system15 to show that treatment of
xenograft cells from the TCRβ-PIM1 PIM1high T-LBL case
with TP-3654 or AZD1208 in combination with dexam-
ethasone resulted in synergistic anti-leukemic activity
(Figure 3B and Online Supplementary Figure S9). In addi-
tion, combination of the PIM inhibitors TP-3654 and
AZD1208 with the BCL2 inhibitor ABT-199 on xenograft
cells from TCRβ-PIM1+ PIM1high T-LBL patient also
revealed strong synergism (CI<0.3) (Online Supplementary
Figure S8B). 
Finally, we used the TCRβ-PIM1+ T-LBL patient-
derived xenograft to evaluate the PIM inhibition and dex-
amethasone combination therapy in vivo (Figure 3C).
Notably, both TP-3654 as well as dexamethasone
monotherapy caused a profound delay in tumor develop-
ment as evaluated by the percentage of hCD45+ tumor
cells in the peripheral blood (Figure 3D). However, com-
bination of PIM inhibition and dexamethasone delayed
leukemic blast recurrence in the periphery with approxi-
mately 40 days (Figure 3D). As expected, these effects
coincided with a significant increase in survival for mice
that received the combination therapy as compared to
both mono-therapies  (P=0.002) (Figure 3E). 
Altogether, our study delivers strong pre-clinical in vivo
evidence for the use of PIM inhibitors, potentially in
combination with glucocorticoids, for the treatment of
human T-ALL and T-LBL, and provides a rationale for
including PIM1high T-ALL and T-LBL patients in clinical tri-
als for second-generation pan-PIM inhibitors.
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